Search

Your search keyword '"Muellner, Julia"' showing total 20 results
Start Over Author "Muellner, Julia"
20 results on '"Muellner, Julia"'

2. Deep Brain Stimulation: When to Test Directional?

Author

Debove, Ines, Petermann, Katrin, Nowacki, Andreas, Nguyen, Thuy-Anh Khoa, Tinkhauser, Gerd, Michelis, Joan Philipp, Muellner, Julia, Amstutz, Deborah, Bargiotas, Panagiotis, Fichtner, Jens, Schläppi, Janine Ai, Krack, Paul, Schuepbach, Michael, Pollo, Claudio, and Lachenmayer, Martin Lenard

Subjects
Neurology, 570 Life sciences, biology, 610 Medicine & health, Neurology (clinical)
Abstract

BACKGROUND Directional deep brain stimulation (DBS) allows for steering of the stimulation field, but extensive and time-consuming testing of all segmented contacts is necessary to identify the possible benefit of steering. It is therefore important to determine under which circumstances directional current steering is advantageous. METHODS Fifty two Parkinson's disease patients implanted in the STN with a directional DBS system underwent a standardized monopolar programming session 5 to 9 months after implantation. Individual contacts were tested for a potential advantage of directional stimulation. Results were used to build a prediction model for the selection of ring levels that would benefit from directional stimulation. RESULTS On average, there was no significant difference in therapeutic window between ring-level contact and best directional contact. However, according to our standardized protocol, 35% of the contacts and 66% of patients had a larger therapeutic window under directional stimulation compared to ring-mode. The segmented contacts warranting directional current steering could be predicted with a sensitivity of 79% and a specificity of 57%. CONCLUSION To reduce time required for DBS programming, we recommend additional directional contact testing initially only on ring-level contacts with a therapeutic window of less than 2.0 mA.

Published
2023
Full Text
View/download PDF

8. Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study

Author

Corvol, Jean-Christophe, Elbaz, Alexis, Vidailhet, Marie, Brice, Alexis, Artaud, Fanny, Bourdain, Frédéric, Brandel, Jean-Philippe, Derkinderen, Pascal, Durif, Franck, Levy, Richard, Pico, Fernando, Rascol, Olivier, Bonnet, Anne-Marie, Bonnet, Cecilia, Brefel-Courbon, Christine, Cormier-Dequaire, Florence, Degos, Bertrand, Debilly, Bérangère, Galitsky, Monique, Grabli, David, Hartmann, Andreas, Klebe, Stephan, Kraemmer, Julia, Lacomblez, Lucette, Leder, Sara, Mangone, Graziella, Mariani, Louise-Laure, Marques, Ana-Raquel, Mesnage, Valérie, Muellner, Julia, Ory-Magne, Fabienne, Planté-Bordeneuve, Violaine, Roze, Emmanuel, Tir, Melissa, You, Hana, Benchetrit, Eve, Socha, Julie, Pineau, Fanny, Vidal, Tiphaine, Pomies, Elsa, Bayet, Virginie, Lesage, Suzanne, Tahiri, Khadija, Bertrand, Hélène, Mallet, Alain, Villeret, Coralie, Mazmanian, Merry, Manseur, Hakima, Hajji, Mostafa, Le Toullec, Benjamin, Brochard, Vanessa, Roy, Monica, Rieu, Isabelle, Bernard, Stéphane, Faurie-Grepon, Antoine, Ihle, J., Artaud, F., Bekadar, S., Mangone, G., Sambin, S., Mariani, LL, Bertrand, H., Rascol, O., Durif, F., Derkinderen, P., Scherzer, C., Elbaz, A., and Corvol, JC

Published
2020
Full Text
View/download PDF

11. Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study

Author

Ihle, J., primary, Artaud, F., additional, Bekadar, S., additional, Mangone, G., additional, Sambin, S., additional, Mariani, LL, additional, Bertrand, H., additional, Rascol, O., additional, Durif, F., additional, Derkinderen, P., additional, Scherzer, C., additional, Elbaz, A., additional, Corvol, JC, additional, Corvol, Jean-Christophe, additional, Elbaz, Alexis, additional, Vidailhet, Marie, additional, Brice, Alexis, additional, Artaud, Fanny, additional, Bourdain, Frédéric, additional, Brandel, Jean-Philippe, additional, Derkinderen, Pascal, additional, Durif, Franck, additional, Levy, Richard, additional, Pico, Fernando, additional, Rascol, Olivier, additional, Bonnet, Anne-Marie, additional, Bonnet, Cecilia, additional, Brefel-Courbon, Christine, additional, Cormier-Dequaire, Florence, additional, Degos, Bertrand, additional, Debilly, Bérangère, additional, Galitsky, Monique, additional, Grabli, David, additional, Hartmann, Andreas, additional, Klebe, Stephan, additional, Kraemmer, Julia, additional, Lacomblez, Lucette, additional, Leder, Sara, additional, Mangone, Graziella, additional, Mariani, Louise-Laure, additional, Marques, Ana-Raquel, additional, Mesnage, Valérie, additional, Muellner, Julia, additional, Ory-Magne, Fabienne, additional, Planté-Bordeneuve, Violaine, additional, Roze, Emmanuel, additional, Tir, Melissa, additional, You, Hana, additional, Benchetrit, Eve, additional, Socha, Julie, additional, Pineau, Fanny, additional, Vidal, Tiphaine, additional, Pomies, Elsa, additional, Bayet, Virginie, additional, Lesage, Suzanne, additional, Tahiri, Khadija, additional, Bertrand, Hélène, additional, Mallet, Alain, additional, Villeret, Coralie, additional, Mazmanian, Merry, additional, Manseur, Hakima, additional, Hajji, Mostafa, additional, Le Toullec, Benjamin, additional, Brochard, Vanessa, additional, Roy, Monica, additional, Rieu, Isabelle, additional, Bernard, Stéphane, additional, and Faurie-Grepon, Antoine, additional

Published
2020
Full Text
View/download PDF

12. Rebound After Fingolimod and a Single Daclizumab Injection in a Patient Retrospectively Diagnosed With NMO Spectrum Disorder—MRI Apparent Diffusion Coefficient Maps in Differential Diagnosis of Demyelinating CNS Disorders

Author

Wagner, Franca, primary, Grunder, Lorenz, additional, Hakim, Arsany, additional, Kamber, Nicole, additional, Horn, Michael P., additional, Muellner, Julia, additional, Hoepner, Robert, additional, Wiest, Roland, additional, Metz, Imke, additional, Chan, Andrew, additional, and Salmen, Anke, additional

Published
2018
Full Text
View/download PDF

13. Depigmenting effect of argan press-cake extract through the down-regulation of Mitf and melanogenic enzymes expression in B16 murine melanoma cells

Author

Jalenques, Isabelle, Guiguet-Auclair, Candy, Derost, Philippe, Joubert, Pauline, Foures, Louis, Hartmann, Andreas, Muellner, Julia, Rondepierre, Fabien, Ouachikh, Omar, Hafidi, Aziz, Boucher, Yves, Dieb, Wisam, Bourhim, Thouria, Villareal, Myra, Gadhi, Chemseddoha, Hafidi, Abdellatif, Isoda, Hiroko, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Psychiatrie Addictologie, CHU Gabriel Montpied, 63 000 Clermont-Ferrand, Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5), and Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique (CNRS)

Subjects
0301 basic medicine, food.ingredient, Tyrosinase, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Clinical Biochemistry, Biomedical Engineering, Argan oil, Bioengineering, Melanin, 03 medical and health sciences, 0302 clinical medicine, food, Cytotoxicity, ComputingMilieux_MISCELLANEOUS, chemistry.chemical_classification, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Cell growth, [SCCO.NEUR]Cognitive science/Neuroscience, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Cell Biology, Microphthalmia-associated transcription factor, Molecular biology, 030104 developmental biology, Enzyme, chemistry, 030220 oncology & carcinogenesis, Original Article, Dopachrome tautomerase, Biotechnology
Abstract

Oil extraction from the kernels of Argania spinosa (L.) Skeels (Sapotaceae), an endemic tree of Morocco, produces argan press-cake (APC) used as a shampoo and to treat sprains, scabies, and for healing wounds. We have previously reported that argan oil has antimelanogenesis effect. Here, we determined if the by-product, APC, has melanogenesis regulatory effect using B16 murine melanoma cells. The effect of APC ethanol extract on cell proliferation and melanin content of B16 cells were measured, and to elucidate the mechanism involved, the expression level of melanogenic enzymes tyrosinase (TYR), dopachrome tautomerase (DCT), and tyrosinase-related protein 1 (TRP1) were determined and mRNA expression level of microphthalmia- associated transcription factor (Mitf) and Tyr genes were quantified. APC ethanol extract showed a significant melanin biosynthesis inhibitory effect on B16 cells in a time-dependent manner without cytotoxicity, which could be due to the decreased expression of TYR, TRP1, and DCT in a time-dependent manner. APC extract down regulated Mitf and Tyr. Decreased TRP1 and DCT levels could be due to post-translational modifications. These results suggest that APC extract may be used as a new source of natural whitening products and may be introduced as an important pharmacological agent for the treatment of hyperpigmentation disorders.

Published
2016
Full Text
View/download PDF

15. Correction: Bee Venom for the Treatment of Parkinson Disease – A Randomized Controlled Clinical Trial

Author

Hartmann, Andreas, primary, Muellner, Julia, additional, Meier, Niklaus, additional, Hesekamp, Helke, additional, van Meerbeeck, Priscilla, additional, Habert, Marie-Odile, additional, Kas, Aurélie, additional, Tanguy, Marie-Laure, additional, Mazmanian, Merry, additional, Oya, Hervé, additional, Abuaf, Nissen, additional, Gaouar, Hafida, additional, Salhi, Sabrina, additional, Charbonnier-Beaupel, Fanny, additional, Fievet, Marie-Hélène, additional, Galanaud, Damien, additional, Arguillere, Sophie, additional, Roze, Emmanuel, additional, Degos, Bertrand, additional, Grabli, David, additional, Lacomblez, Lucette, additional, Hubsch, Cécile, additional, Vidailhet, Marie, additional, Bonnet, Anne-Marie, additional, Corvol, Jean-Christophe, additional, and Schüpbach, Michael, additional

Published
2016
Full Text
View/download PDF

19. Results of a Randomized Clinical Trial of Speech after Early Neurostimulation in Parkinson's Disease

Author

Pinto, Serge, Nebel, Adelheid, Rau, Jorn, Espesser, Robert, Maillochon, Pauline, Niebuhr, Oliver, Krack, Paul, Witjas, Tatiana, Ghio, Alain, Cuartero, Marie-Charlotte, Timmermann, Lars, Schnitzler, Alfons, Hesekamp, Helke, Meier, Niklaus, Muellner, Julia, Haelbig, Thomas D., Moeller, Bettina, Paschen, Steffen, Paschen, Laura, Volkmann, Jens, Barbe, Michael T., Fink, Gereon R., Becker, Johannes, Reker, Paul, Kuehn, Andrea A., Schneider, Gerd-Helge, Fraix, Valerie, Seigneuret, Eric, Kistner, Andrea, Rascol, Olivier, Brefel-Courbon, Christine, Ory-Magne, Fabienne, Hartmann, Christian J., Wojtecki, Lars, Fradet, Anne, Maltete, David, Damier, Philippe, Le Dily, Severine, Sixel-Doering, Friederike, Benecke, Petra, Weiss, Daniel, Waechter, Tobias, Pinsker, Marcus O., Regis, Jean, Thobois, Stephane, Polo, Gustavo, Houeto, Jean-Luc, Hartmann, Andreas, Knudsen, Karina, Vidailhet, Marie, Schuepbach, Michael, Deuschl, Gunther, Pinto, Serge, Nebel, Adelheid, Rau, Jorn, Espesser, Robert, Maillochon, Pauline, Niebuhr, Oliver, Krack, Paul, Witjas, Tatiana, Ghio, Alain, Cuartero, Marie-Charlotte, Timmermann, Lars, Schnitzler, Alfons, Hesekamp, Helke, Meier, Niklaus, Muellner, Julia, Haelbig, Thomas D., Moeller, Bettina, Paschen, Steffen, Paschen, Laura, Volkmann, Jens, Barbe, Michael T., Fink, Gereon R., Becker, Johannes, Reker, Paul, Kuehn, Andrea A., Schneider, Gerd-Helge, Fraix, Valerie, Seigneuret, Eric, Kistner, Andrea, Rascol, Olivier, Brefel-Courbon, Christine, Ory-Magne, Fabienne, Hartmann, Christian J., Wojtecki, Lars, Fradet, Anne, Maltete, David, Damier, Philippe, Le Dily, Severine, Sixel-Doering, Friederike, Benecke, Petra, Weiss, Daniel, Waechter, Tobias, Pinsker, Marcus O., Regis, Jean, Thobois, Stephane, Polo, Gustavo, Houeto, Jean-Luc, Hartmann, Andreas, Knudsen, Karina, Vidailhet, Marie, Schuepbach, Michael, and Deuschl, Gunther

Abstract

BackgroundThe EARLYSTIM trial demonstrated for Parkinson's disease patients with early motor complications that deep brain stimulation of the subthalamic nucleus (STN-DBS) and best medical treatment (BMT) was superior to BMT alone. ObjectiveThis prospective, ancillary study on EARLYSTIM compared changes in blinded speech intelligibility assessment between STN-DBS and BMT over 2 years, and secondary outcomes included non-speech oral movements (maximum phonation time [MPT], oral diadochokinesis), physician- and patient-reported assessments. MethodsSTN-DBS (n = 102) and BMT (n = 99) groups underwent assessments on/off medication at baseline and 24 months (in four conditions: on/off medication, ON/OFF stimulation-for STN-DBS). Words and sentences were randomly presented to blinded listeners, and speech intelligibility rate was measured. Statistical analyses compared changes between the STN-DBS and BMT groups from baseline to 24 months. ResultsOver the 2-year period, changes in speech intelligibility and MPT, as well as patient-reported outcomes, were not different between groups, either off or on medication or OFF or ON stimulation, but most outcomes showed a nonsignificant trend toward worsening in both groups. Change in oral diadochokinesis was significantly different between STN-DBS and BMT groups, on medication and OFF STN-DBS, with patients in the STN-DBS group performing slightly worse than patients under BMT only. A signal for clinical worsening with STN-DBS was found for the individual speech item of the Unified Parkinson's Disease Rating Scale, Part III. ConclusionAt this early stage of the patients' disease, STN-DBS did not result in a consistent deterioration in blinded speech intelligibility assessment and patient-reported communication, as observed in studies of advanced Parkinson's Disease. (c) 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

20. Long-Term Outcome and Neuroimaging of Deep Brain Stimulation in Holmes Tremor: A Case Series.

Author

Bargiotas P, Nguyen TAK, Bracht T, Mürset M, Nowacki A, Debove I, Muellner J, Michelis JP, Pollo C, Schüpbach WMM, and Lachenmayer ML

Subjects
Activities of Daily Living, Humans, Neuroimaging, Quality of Life, Treatment Outcome, Tremor diagnostic imaging, Tremor therapy, Deep Brain Stimulation, Essential Tremor therapy
Abstract

Background: Different deep brain stimulation (DBS) targets have been suggested as treatment for patients with pharmacologically refractory Holmes tremor (HT). We report the clinical and quality of life (QoL) long-term (up to nine years) outcome in four patients with HT treated with DBS (in thalamic ventral intermediate nucleus-VIM or in dentato-rubro-thalamic tract-DRTT)., Materials and Methods: The patients underwent routine clinical evaluations before and after DBS (typically annually). Tremor severity and activities of daily living (ADL) were quantified by the Fahn-Tolosa-Marin Tremor-Rating-Scale (FTMTRS). QoL was assessed using the RAND SF-36-item Health Survey (RAND SF-36). In addition, we computed, in all four patients, the VTA based on the best stimulation settings using heuristic approaches included in the open source toolbox LEAD-DBS., Results: In all patients, tremor and ADL improved significantly at one-year post-DBS follow-up (34-61% improvement in FTMTRS total score compared to baseline). In three out of four patients, the improvement of tremor was sustained no longer than two to three years and only in one patient was sustained up to nine years. In this patient, the largest intersection between VTA and DBS target has been observed. Scores for ADL deteriorated over the course of time, reaching worse levels compared to baseline already during the three-year post-DBS follow-up, in three out of four patients. Physical and mental health component scores of RAND SF-36 had very different outcome between patients and follow-ups and were not associated with tremor-related outcomes., Conclusions: The benefits of DBS in HT might not be always long lasting. Although QoL slightly improved, this change seemed to be independent of the motor outcome following DBS. The estimation of DBS target and VTA proximity could be a useful tool for DBS clinicians in order to facilitate the DBS programming process and optimize DBS treatment., (© 2021 International Neuromodulation Society.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results